This is one of the most important patents in the history of stem cell IP. It essentially covers the hematopoietic CD34+ stem cell. The patent has 3 independent claims, the first covering a population of hematopoietic cells in general, the second covering hematopoietic cells from blood, and the third covering hematopoietic cells which are recognized by a specific antibody, whose target was latered named "CD34". It is this patent, and another similar one by Civin that were litigated and successfully won in Johns Hopkins Univ. v. CellPro, Inc., 152 F.3d 1342 (Fed. Cir. 1998).
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.